Endocrinology

Latest News

Viking Therapeutics Oral Antiobesity Agent Returns Positive Results in Small Study / image credit weight loss: ©Brovarky/stock.adobe.com
Viking Therapeutics Oral Antiobesity Agent Returns Positive Results in Small Study

March 27th 2024

The once daily tablet, VK2375, is headed to a phase 2 trial later this year and is an oral version of Viking's investigational injectable GLP-1/GIP mimetic currently in phase 2.

©Timon/stock.adobe.com
Medicare Will Cover AOM Semaglutide for Cardiovascular Risk Reduction: A First

March 22nd 2024

Lanifibranor Plus Empagliflozin Effective in T2D, MASH: Proof-of-Concept Ph2 Findings / image credit organs:©marina_ua/stock.adobe.com
Lanifibranor Plus Empagliflozin Effective in T2D, MASH: Proof-of-Concept Ph2 Findings

March 20th 2024

In Pregnant Women with T1D, Higher Time-in-Range Improves Maternal, Neonatal Outcomes: Daily Dose / image credit: ©New Africa/AdobeStock
In Pregnant Women with T1D, Higher Time-in-Range Improves Maternal, Neonatal Outcomes: Daily Dose

March 13th 2024

Early Detection of CKD Progression in Primary Care: Daily Dose / image credit: ©New Africa/AdobeStock
Early Detection of CKD Progression in Primary Care: Daily Dose

March 12th 2024

Latest CME Events & Activities

More News

© 2024 MJH Life Sciences

All rights reserved.